Furthest along
16 approved
7 in Phase 3
Drugs
32
in active trials · 130 in all
Trials
100 active
497 since 2021
Drugs32
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 23 Jan 2027Phase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | 23 Jan 2027 · Phase 4 trial completes | ||||
| Also tested for | Giant Cell Tumor of Bone, Osteoporosis and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 13 Apr 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 13 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis and 8 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 4 May 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 4 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Osteogenesis Imperfecta | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 29 May 2027Phase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | 29 May 2027 · Phase 4 trial completes | ||||
| Also tested for | Cardiovascular Disease, Myocardial Infarction and 6 more | ||||
| Open drug page | |||||
Calcium-sensing receptor agonist |
Approved | 30 Jun 2027Phase 3 trial completes | |||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Secondary Hyperparathyroidism, Chronic Kidney Disease | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Approved | 30 Jun 2027Phase 3 trial completes | |||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation and 6 more | ||||
| Open drug page | |||||
Avacopannot checked |
Complement 5a receptor antagonist |
Approved | 18 Jul 2027Phase 3 trial completes | ||
| Next date | 18 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Vasculitis | ||||
| Open drug page | |||||
— |
Approved | 31 Jul 2027Phase 3 trial completes | |||
| Next date | 31 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Neovascular Age-related Macular Degeneration, nAMD | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 24 Sep 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 24 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Extensive Stage Small Cell Lung Cancer, Small Cell Lung Cancer and 7 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 24 Nov 2027Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 24 Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | B Cell Precursor Acute Lymphoblastic Leukemia, Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) and 7 more | ||||
| Open drug page | |||||
Phosphodiesterase 4 inhibitor |
Approved | 21 Mar 2028Phase 3 trial completes | |||
| Next date | 21 Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Behçet Disease, Active Juvenile Psoriatic Arthritis and 5 more | ||||
| Open drug page | |||||
Uric acid-specific enzyme |
Approved | 18 Jun 2028Phase 3 trial completes | |||
| Next date | 18 Jun 2028 · Phase 3 trial completes | ||||
| Also tested for | Uncontrolled Gout | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 1 Jul 2028Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation and 2 more | ||||
| Open drug page | |||||
Thrombopoietin receptor agonist |
Approved | 14 Sep 2029Phase 3 trial completes | |||
| Next date | 14 Sep 2029 · Phase 3 trial completes | ||||
| Also tested for | Chemotherapy-induced Thrombocytopenia, Primary Immune Thrombocytopenia | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | — | |||
| How it works | An antibody | ||||
| Also tested for | Migraine | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | — | |||
| How it works | An antibody | ||||
| Also tested for | Thyroid Eye Disease | ||||
| Open drug page | |||||
Pembrolizumab biosimilar candidate |
Phase 3 | 14 Dec 2026soonPhase 3 trial completes | |||
| Next date | 14 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | ||||
| Open drug page | |||||
GLP-1 agonist + GIPR antagonist antibody |
Phase 3 | 21 Jan 2027Phase 3 trial completes | |||
| How it works | Copies GLP-1 | ||||
| Next date | 21 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 10 more | ||||
| Open drug page | |||||
— |
Phase 3 | 19 Apr 2027Phase 3 trial completes | |||
| Next date | 19 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Relapsing-remitting Multiple Sclerosis (RRMS) | ||||
| Open drug page | |||||
— |
Phase 3 | 25 Jan 2028Phase 3 trial completes | |||
| Next date | 25 Jan 2028 · Phase 3 trial completes | ||||
| Also tested for | Melanoma | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings23
Since Feb 2024 · All on SEC.gov- 3 NovReported quarterly results · SEC 8-K
- 27 OctChanged a director or officer · SEC 8-K
- 4 AugReported quarterly results · SEC 8-K
- 31 JulFiled a report · SEC 8-K
- 20 MayFiled a report · SEC 8-K
- 19 MayChanged a director or officer · SEC 8-K
- 30 AprReported quarterly results · SEC 8-K
- 22 AprChanged a director or officer · SEC 8-K
- 19 FebOffered new securities · 1 prospectus (424B2)
- 19 FebSigned a material agreement · SEC 8-K
- 17 FebOffered new securities · 1 prospectus (424B3)
- 3 FebReported quarterly results · SEC 8-K
- 30 JanFiled a report · SEC 8-K
- 4 Nov 2025Reported quarterly results · SEC 8-K
- 5 Aug 2025Reported quarterly results · SEC 8-K
- 27 May 2025Filed a report · SEC 8-K
- 1 May 2025Reported quarterly results · SEC 8-K
- 4 Feb 2025Reported quarterly results · SEC 8-K
- 30 Oct 2024Reported quarterly results · SEC 8-K
- 6 Aug 2024Reported quarterly results · SEC 8-K
- 3 Jun 2024Changed a director or officer · SEC 8-K
- 2 May 2024Reported quarterly results · SEC 8-K
- 6 Feb 2024Reported quarterly results · SEC 8-K
About
- No active trial
- 98 other drugs
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev